ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt
Release Date: 04/04/2012

ClinicalTrials.gov ID: NCT00664521

## Study Identification

| | |
|---|---|
| Unique Protocol ID: | 28155 |
| Brief Title: | Atacicept in Combination With Rituximab in Subjects With Rheumatoid Arthritis ( August III ) |
| Official Title: | A Randomized, Double-blind, Placebo Controlled, Multi-centre, Exploratory, Pilot, Phase II Trial of 150mg Atacicept Given Subcutaneously in Combination With Rituximab in Subjects With Rheumatoid Arthritis. |
| Secondary IDs: | |

## Study Status

| | |
|---|---|
| Record Verification: | April 2012 |
| Overall Status: | Completed |
| Study Start: | March 2008 |
| Primary Completion: | October 2010 [Actual] |
| Study Completion: | January 2011 [Actual] |

## Sponsor/Collaborators

| | |
|---|---|
| Sponsor: | Merck KGaA |
| Responsible Party: | Sponsor |
| Collaborators: | |

## Oversight

| | |
|---|---|
| FDA Regulated?: | Yes |
| Applicable Trial?: | Section 801 Clinical Trial? No<br>Delayed Posting? No |
| IND/IDE Protocol?: | No |
| Review Board: | Approval Status: Approved<br>Approval Number: LAUSUNTO NRO § 5/2008 (Dnro 425<br>Board Name: The Hospital District of Helsinki and Uusimaa Federation of Municipalities<br>Board Affiliation: Finland - Ethics Committee<br>Phone: 35-895-427-0013<br>Email: paula.maasilta@helsinki.fi |
| Data Monitoring?: | |
| Plan to Share Data?: | |

Oversight Authorities: Finland: Finnish Medicines Agency
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Sweden: Medical Products Agency
United Kingdom: Medicines and Healthcare Products Regulatory Agency

## Study Description

Brief Summary: The primary objective of this study is to assess the safety and tolerability of combined treatment with atacicept and rituximab in subjects with active rheumatoid arthritis receiving re-treatment with rituximab.

Detailed Description:

## Conditions

Conditions: Rheumatoid Arthritis

Keywords:

## Study Design

Study Type: Interventional

Primary Purpose: Treatment

Study Phase: Phase 2

Intervention Model: Parallel Assignment

Number of Arms: 2

Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)

Allocation: Randomized

Endpoint Classification:

Enrollment: 68 [Actual]

## Arms and Interventions

| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Biological/Vaccine: Rituximab<br>Rituximab 1000 mg IV infusion, 2nd 1000 mg IV infusion given 2 weeks later, followed 28 days later by atacicept/placebo 150 mg/mL SC once weekly for 25 weeks |
| Experimental: 2 | Biological/Vaccine: Atacicept / placebo<br>Atacicept/placebo 150 mg/mL SC once weekly for 25 weeks, given in combination with rituximab 1000 mg IV infusion on study day 10, 2nd 1000 mg IV infusion given 2 weeks later |

## Outcome Measures

Primary Outcome Measure:

1. Nature, incidence and severity of adverse events (AEs)

[Time Frame: Every 2 - 6 weeks] [Safety Issue: Yes] null

2. Proportion of subjects who develop IgG <3 g/L
   [Time Frame: Every 2 - 6 weeks] [Safety Issue: Yes] null
3. Changes / abnormalities in vital signs/ routine safety lab parameters
   [Time Frame: Every 2 - 6 weeks] [Safety Issue: Yes] null
4. Changes over time in vaccine immunization status
   [Time Frame: Every 2 - 6 weeks] [Safety Issue: Yes] null

Secondary Outcome Measure:

5. ACR and DAS28 composite scores at week 26
   [Time Frame: Every 2 - 6 weeks] [Safety Issue: Yes] null

## Eligibility

| | |
|---|---|
| Minimum Age: | 18 Years |
| Maximum Age: | |
| Gender: | Both |
| Accepts Healthy Volunteers?: | No |

Criteria: Inclusion Criteria:

- Male and female subjects
- >18 years of age at the time of Informed Consent
- who have rheumatoid arthritis (satisfying American College of Rheumatology criteria)
- a disease history of at least 12 months.
- Subjects must have active disease defined by
  - >8 swollen joints (out of 66)
  - >8 tender joints (out of 68)
  - CRP >6 mg/L
  - ESR >28 mm/h.
- Subjects must have received previous treatment with rituximab and must be candidates for re-treatment with rituximab.
- Female subjects of childbearing potential must be willing to avoid pregnancy by using an adequate method of contraception for 4 weeks before SD1, during the treatment period and for 12 months after the last dose of rituximab, and must have a negative urine pregnancy test at the screening visit and SD1.

Exclusion Criteria:

- Neurological disease
- Inflammatory joint disease other than rheumatoid arthritis
- Any contraindication to rituximab as per national label
- Use of disease-modifying anti-rheumatic drugs (DMARDs; including methotrexate) for less than 3 months or change in dosing regimen within 28 days before SD1, or methotrexate dose regimen >25 mg/week
- Participation in any interventional clinical trial within 1 month before SD1 (or within 5 half-lives of the investigated compound before SD1, whichever is longer)
- Prednisone dose regimen >10 mg/day (or equivalent), or change in steroid dosing regimen within 28 days before SD1
- Active or latent tuberculosis within the year before screening or major infection requiring hospitalization or intravenous anti-infectives within 28 days before SD1
- Serum IgG below 6 g/L
- Known hypersensitivity to atacicept or to any of the components of the formulated atacicpet

- Known hypersensitivity to rituximab, to any of the components of the formulated rituximab or to murine proteins
- Breastfeeding or pregnancy

## Contacts/Locations

Study Officials:

Locations: Sweden
Research Site
Stockholm, Sweden

Netherlands
Research Site
Amsterdam, Netherlands

United Kingdom
Research Site
Norwich, United Kingdom

France
Research Site
Paris, France

Research Site
Strasbourg, France

Research Site
Nice, France

Sweden
Research Site
Malmö, Sweden

United Kingdom
Research Site
Newcastle, United Kingdom

## References

Citations:

Links:

Study Data/Documents: